Home MAPK MNK

MNK

Choose Selective MNK Inhibitors
Isoform-selective Inhibitors

MNK Products

  • All (4)
  • MNK Inhibitors (4)
  • New MNK Products
Catalog No. Product Name Information Product Use Citations Product Validations
S6658 ETC-206 (AUM 001) ETC-206 (AUM 001, ETC-1907206) is an orally available highly selective small-molecule MNK 1/2 inhibitor with IC50s of 64 nM and 86 nM, respectively.
S6888 SEL201 SEL-201 (SLV-2436, SEL201-88) is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2 with IC50 of 10.8  nM and 5.4 nM, respectively.
S7421 CGP 57380 CGP 57380 is a potent MNK1 inhibitor with IC50 of 2.2 μM, exhibiting no inhibitory activity on p38, JNK1, ERK1 and -2, PKC, or c-Src-like kinases. CGP 57380 upregulates β-catenin and potentiates radiation-induced apoptosis.
J Cancer, 2020, 11(4):990-996
Bioorg Med Chem, 2018, 26(16):4602-4614
Cancer Lett, 2016, 10.1016/j.canlet.2016.02.052
S8275 Tomivosertib (eFT-508) Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
J Clin Invest, 2021, 140752
Elife, 2020, 9e60151
Cell Rep Med, 2020, 1(8):100131
S6658 ETC-206 (AUM 001) ETC-206 (AUM 001, ETC-1907206) is an orally available highly selective small-molecule MNK 1/2 inhibitor with IC50s of 64 nM and 86 nM, respectively.
S6888 SEL201 SEL-201 (SLV-2436, SEL201-88) is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2 with IC50 of 10.8  nM and 5.4 nM, respectively.
S7421 CGP 57380 CGP 57380 is a potent MNK1 inhibitor with IC50 of 2.2 μM, exhibiting no inhibitory activity on p38, JNK1, ERK1 and -2, PKC, or c-Src-like kinases. CGP 57380 upregulates β-catenin and potentiates radiation-induced apoptosis.
J Cancer, 2020, 11(4):990-996
Bioorg Med Chem, 2018, 26(16):4602-4614
Cancer Lett, 2016, 10.1016/j.canlet.2016.02.052
S8275 Tomivosertib (eFT-508) Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
J Clin Invest, 2021, 140752
Elife, 2020, 9e60151
Cell Rep Med, 2020, 1(8):100131
Tags: MNK activty | MNK inhibitor | MNK inhibitor review